Group 1 - The company does not currently have products directly used in solid-state batteries, but its sodium carbonate and phosphate products are basic raw materials for some solid-state battery cathodes [1] - The company holds a 50% stake in Nigeria's BCT Company through its wholly-owned subsidiary, Hebang Bio (Hong Kong) Investment Co., Ltd [1] - BCT Company is primarily engaged in the mining, washing, and sales of lithium and tin ores, currently holding exploration rights for 15 lithium mines and 6 tin mines [1] Group 2 - BCT Company controls 60% of "Deep Earth Mineral Resources Limited," which has exploration rights for 5 lithium mines, and "BC Mining Company Limited," which has exploration rights for 2 lithium mines [1]

Core Points - Hebang Biotechnology announced the need to pay corporate income tax and late fees totaling 71,473,969.37 yuan for the period from January 1, 2023, to December 31, 2023 [1] - As of the date of the announcement, the company has completed the payment of the aforementioned tax and late fees, and this matter does not involve any administrative penalties [1]

Market Performance - The agricultural chemical sector increased by 0.64% on September 11, with Dongfang Tieta leading the gains [1] - The Shanghai Composite Index closed at 3875.31, up 1.65%, while the Shenzhen Component Index closed at 12979.89, up 3.36% [1] Stock Performance - Dongfang Tieta (002545) closed at 12.96, up 6.23% with a trading volume of 487,700 shares and a transaction value of 623 million [1] - Bai'ao Chemical (603360) closed at 25.20, up 2.56% with a trading volume of 150,100 shares and a transaction value of 373 million [1] - Other notable stocks include Yaji International (000893) at 38.46, up 2.04%, and Beisimei (300796) at 10.53, up 2.03% [1] Capital Flow - The agricultural chemical sector experienced a net outflow of 281 million from institutional investors, while retail investors saw a net inflow of 153 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Yanhai Co. (000792) had a net inflow of 99.18 million from institutional investors, while it faced a net outflow of 62.99 million from speculative funds [3] - Bai'ao Chemical (603360) saw a net inflow of 18.38 million from institutional investors but a net outflow of 24.29 million from speculative funds [3] - Guotian Co. (002170) had a net inflow of 8.12 million from institutional investors, with a significant net inflow of 46.84 million from speculative funds [3]

Core Points - The company, Hebang Biotechnology (603077.SH), announced the need to pay a total of 71.474 million yuan in corporate income tax and late fees for the period from January 1, 2023, to December 31, 2023 [1] - As of the date of the announcement, the company has completed the payment of the aforementioned tax and late fees, and this matter does not involve any administrative penalties [1] - The payment of the tax and late fees will be recorded in the company's 2025 financial results, with an expected impact of 71.474 million yuan on the net profit attributable to shareholders of the listed company for the year 2025, subject to the final audited financial statements for that year [1]

Core Points - The company, Hebang Biotechnology (603077.SH), announced the need to pay a total of 71.474 million yuan in corporate income tax and late fees for the period from January 1, 2023, to December 31, 2023 [1] - As of the date of the announcement, the company has completed the payment of the aforementioned tax and late fees, and this matter does not involve any administrative penalties [1] - The payment of the tax and late fees will be recorded in the company's profit and loss for the year 2025, and it is expected to impact the net profit attributable to shareholders of the listed company by 71.474 million yuan, subject to the final audited financial statements for 2025 [1]

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 15 日（星期一）至 09 月 19 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 jsy@hebang.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 四川和邦生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 20 日发布《四川和邦生物科技股份有限公司 2025 年半年度报告》，为便于广大投资 者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 22 日（星期一）16:00-17:00 举行 2025 年半年度业绩说明会，就投资 者关心的问题进 ...

证券代码：603077 证券简称：和邦生物 公告编号：2025-042 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 关于公司补缴税款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、对公司的影响 根据《企业会计准则第 28 号--会计政策、会计估计变更和差错更正》相关 规定，上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据追 溯调整。公司补缴上述税款及滞纳金将计入 2025 年当期损益，预计将影响公司 2025 年度归属于上市公司股东的净利润 71,473,969.37 元，最终以 2025 年度经 审计的财务报表为准。 特此公告。 四川和邦生物科技股份有限公司董事会 2025 年 9 月 12 日 四川和邦生物科技股份有限公司（以下简称"公司"）根据税法相关规定对 涉税业务开展了自查，现将有关情况公告如下： 一、基本情况 经自查，公司需补缴 2023 年 1 月 1 日至 2023 年 12 月 31 日企业所得税及滞 纳金合计 71,473,969.37 元。截至本公告 ...

Group 1 - The company, Hebang Biology (603077.SH), announced that it needs to pay a total of 71.474 million yuan in corporate income tax and late fees for the period from January 1, 2023, to December 31, 2023 [1] - As of the date of the announcement, the company has completed the payment of the aforementioned tax and late fees [1] - This matter does not involve any administrative penalties [1]

Group 1 - The company has completed the registration of its overseas investment project in Nigeria, holding a 50% stake in BULLCREST MINERAL RESOURCES LIMITED (BCT), which focuses on lithium and tin mining [1][2] - BCT currently possesses exploration rights for 15 lithium mines and 6 tin mines, along with additional rights through its subsidiaries [1] - The company has received the necessary approvals from the Sichuan Provincial Development and Reform Commission and the Sichuan Provincial Department of Commerce for its overseas investment [2] Group 2 - The overseas investment project is located in Kwara State, Nigeria, with a 50% ownership split between the company and AFRICORP HOLDINGS LIMITED [2] - The company acknowledges potential risks associated with the new operating environment, including cultural, legal, and policy-related challenges, and emphasizes the importance of risk assessment and management [2]

Group 1 - The company, Hebang Biology, announced that it holds a 50% stake in Nigeria's BULLCREST MINERAL RESOURCES LIMITED (BCT) through its wholly-owned subsidiary, Hebang Biology (Hong Kong) Investment Co., Ltd [2] - BCT, established in 2023 under Nigerian federal law, is primarily engaged in the mining, washing, and sales of lithium and tin ores, currently holding 15 lithium and 6 tin mining exploration rights [2] - The company has completed the registration of its overseas investment and received the Overseas Investment Project Filing Notification from the Sichuan Provincial Development and Reform Commission [2]